Recombinant Granulocyte Colony-Stimulating Factor

Phase 3Biologic

Recombinant Granulocyte Colony-Stimulating Factor is one of 160 biologic programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

159

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaRecruiting

Acute Lymphoblastic Leukemia in RemissionRecruiting

Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecruiting

Primary MyelofibrosisRecruiting

Acute Leukemia of Ambiguous LineageRecruiting

Multiple MyelomaRecruiting

LymphomaRecruiting

Plasma Cell LeukemiaRecruiting

Acute Myeloid LeukemiaPhase 2

Recruiting

Acute Lymphoblastic Leukemia in RemissionPreclinical

Recruiting

Chronic Myeloid Leukemia, BCR-ABL1 PositivePhase 1

Recruiting

Primary MyelofibrosisPhase 2

Recruiting

Acute Leukemia of Ambiguous LineagePhase 2

Recruiting

Multiple MyelomaPhase 3

Recruiting

LymphomaPhase 2

Recruiting

Plasma Cell LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Recombinant Granulocyte Colony-Stimulating Factor

FFred Hutchinson Cancer Center

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Acute Myeloid Leukemia

NCT04797767

ApprovedRecruiting

Multiple Myeloma

NCT07101445

Q2 2029

Phase 1Recruiting

Chronic Myeloid Leukemia, BCR-ABL1 Positive

NCT07020533

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT07046078

Q3 2029

Phase 2Recruiting

Primary Myelofibrosis

NCT04370301

Q4 2029

Phase 2Recruiting

Lymphoma

NCT04871607

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Recruiting·UUniversity of Washington·Phase 1/2·NCT04797767·62 enrolled

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Terminated·UUniversity of Washington·Phase 1·NCT04196010·13 enrolled

Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT04195945·60 enrolled

Lymphoma1 trial

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recruiting·—·Phase 2·NCT04871607·33 enrolled

Myeloid Neoplasm1 trial

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT03531918·66 enrolled

Toxic Epidermal Necrolysis1 trial

G-CSF in the Treatment of Toxic Epidermal Necrolysis

Completed·UUniversity of Liege·Phase 4·NCT02739295·10 enrolled

Plasma Cell Leukemia1 trial

Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07605416·74 enrolled

5 more indications

Chronic Myeloid Leukemia, BCR-ABL1 Positive1 trial

A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant

Recruiting·CCity of Hope Medical Center·Phase 1·NCT07020533·46 enrolled

Multiple Myeloma1 trial

Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)

Recruiting·EEmory University·Approved·NCT07101445·94 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07046078·20 enrolled

Primary Myelofibrosis1 trial

Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04370301·20 enrolled

Acute Lymphoblastic Leukemia in Remission1 trial

A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT03670966·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Recombinant Granulocyte Colony-Stimulating Factor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Granulocyte Colony-Stimulating Factor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Granulocyte Colony-Stimulating Factor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fred Hutchinson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: FFred Hutchinson Cancer Center

Recombinant Granulocyte Colony-Stimulating Factor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Q3 2029

Q4 2029

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Lymphoma1 trial

Myeloid Neoplasm1 trial

Toxic Epidermal Necrolysis1 trial

Plasma Cell Leukemia1 trial

Chronic Myeloid Leukemia, BCR-ABL1 Positive1 trial

Multiple Myeloma1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Primary Myelofibrosis1 trial

Acute Lymphoblastic Leukemia in Remission1 trial

References

Drug Info

Quick Facts

Related News